We allocated 76 men scheduled for radical retropubic prostatectomy to peri-operative lidocaine 2% or saline 0.9%: a pre-operative 0.075 ml.kg À1 intravenous bolus; an intra-operative intravenous infusion at 0.075 ml.kg À1 .h À1 ; and 24 hours' postoperative subcutaneous infusion at 0.075 ml.kg
Introduction
Intravenous lidocaine reduces pain and shortens the duration of ileus and hospital stay after surgery [1] [2] [3] [4] . A subcutaneous infusion of lidocaine may be similarly effective and is potentially safer than intravenous infusion by reducing the variability in plasma concentration. We conducted this randomised controlled trial to test whether intra-operative intravenous lidocaine combined with a postoperative 24-h subcutaneous lidocaine infusion, would decrease pain and hospital stay after radical retropubic prostatectomy.
Methods
The Research Ethics Units at Austin and Box Hill hospitals approved this registered study. Two investigators (LW, CR) recruited men scheduled for open retropubic radical prostatectomy, who were older than 18 years and ASA physical status < 4. All participants gave written informed consent.
We did not study patients with any of the following: intolerance to opioids local anaesthetics or non-steroidal anti-inflammatory drugs; second or third degree heart block, sino-atrial block without pacemaker; prescribed Class 1 anti-arrhythmic drugs or amiodarone; epilepsy, seizures, cognitive impairment, or craniotomy within the last five years; myasthenia gravis; pre-operative morphine consumption > 3 mg. . An independent statistician generated a computerised sequence of 76 allocation codes, 38 for each group (www.randomization.com). Pharmacy staff sealed the allocation codes into sequentially numbered opaque envelopes. The sequence was decoded after we had analysed the data. The study participants, surgeons, anaesthetists, nurses, and all peri-operative staff were blinded to treatment assignments. On the day of surgery, an independent clinical pharmacist prepared 50-ml and 200-ml infusions for intra-operative and postoperative use, respectively, labelled "2% lignocaine or saline", which contained lidocaine 2% or saline 0.9%. Before induction of anaesthesia, we injected 0.075 ml.kg À1 of the infusate intravenously over three minutes, which we then infused at 0.075 ml.kg
À1
.h
until the end of surgery. We induced anaesthesia intravenously with fentanyl 3 lg.kg À1 and propofol 1-3 mg.kg
. We used a non-depolarising muscle relaxant to facilitate tracheal intubation. We maintained anaesthesia with sevoflurane titrated to bispectral indices of 40-60. We monitored ECG, pulse oximetry, capnography, invasive arterial blood pressure and core body temperature. We infused fentanyl 2.5 lg.kg
, supplemented at the discretion of the anaesthetist with 1-2 lg.kg À1 boluses.
We maintained infusions of Hartmann's or Plasmalyte solutions at 5 ml.kg
. We replaced blood loss with a colloid: we transfused blood for [haemoglobin] < 80 g.l À1 or < 90 g.l À1 when we anticipated further bleeding. We maintained the core temperature above 36°C with warm fluids and forced-air warming (3M Bair Hugger â Total Temperature Management System, Critical Assist, Australia). We injected dexamethasone 8 mg and ondansetron 8 mg intravenously for antiemetic prophylaxis. We gave paracetamol 1 g intravenously and ketorolac 30 mg intramuscularly about 30 min before the end of surgery and stopped the fentanyl infusion. We stopped the intravenous lidocaine infusion after tracheal extubation. We did not use any local or regional anaesthesia.
In recovery, we inserted a subcutaneous cannula in the upper arm or abdomen (BD Saf-T-Intima TM ; BD Medical, Sandy, UT, USA), and started the allocated 0.075 ml.kg . Intravenous metoclopramide 20 mg or droperidol 2.5 mg were used to treat nausea or vomiting. Participants could drink water in recovery and could eat on the ward. Participants sat out of bed six hours after surgery and walked with the assistance of physiotherapists the next day. The subcutaneous infusion was discontinued at 24 postoperative hours, after which participants could take oral oxycodone 10-20 mg every four hours as required for discharge. The urinary catheter remained in situ for two postoperative weeks.
The primary outcome was postoperative hospital stay, from the end of surgery to hospital discharge. The criteria for discharge were unassisted walking, eating and drinking without nausea or vomiting, defaecation, satisfactory oral analgesia and no evidence of medical or surgical complications, particularly infection. The secondary outcomes were postoperative pain, analgesia, side effects, and participant satisfaction. We measured pain at the incision site with a 0-10 mm visual analogue scale, at rest and on coughing, hourly for four consecutive postoperative hours and then every 4 h for 20 h and then every 6-12 h for the next 24 h. We recorded morphine consumption hourly for 24 postoperative hours, nausea, vomiting and rescue antiemetic administration, unless given for a different indication, for instance metoclopramide for prokinesis. We categorised postoperative sedation as: awake; occasionally drowsy and easy to rouse; often drowsy but easy to rouse; somnolent and difficult to rouse; sleeping. We categorised participant satisfaction as: very dissatisfied; dissatisfied; ambivalent; satisfied; very satisfied. We asked participants if they had experienced any of the following symptoms in the first 24 postoperative hours: numbness around their mouth; dizziness or headache; muscle twitching; visual or auditory hallucinations or confusion. We measured plasma lidocaine concentrations at the end of surgery and 24 h later with a calibrated reversedphase high-pressure liquid chromatography assay.
We calculated that 38 participants in each group would have an 80% power to detect an 18 h reduction in hospital stay from the mean (SD) duration in 2009 of 98.4 (28.8) hours at a significance level of 0.05 [6] . We used t-tests and Mann-Whitney U-tests as appropriate for continuous data and chi-squared tests for categorical data with the Newcombe-Wilson method to calculate the 95% confidence interval [7] . We considered p values < 0.05 significant. We used standard methods to report this trial [8] .
Results
We recruited 76 men ( Fig. 1 and Table 1 ), 56 in Austin hospital and 20 in Box Hill hospital. We excluded one man in the lidocaine group whose operation was cancelled after anaphylaxis to cephalosporin antibiotic, given on induction of anaesthesia. We analysed the outcomes for another man in the lidocaine group who was not given intra-operative and postoperative infusions after lidocaine 1 g was inadvertently injected before anaesthetic induction; a brief period of hypotension was treated with a single dose of metaraminol.
Lidocaine reduced the postoperative stay by a mean (95% CI) of 1.3 (0.3-2.4) days, p = 0.017, from a mean (SD) of 4.6 (3.2) days with saline (Fig. 2 ). There were no differences between Austin and Box Hill hospitals in mean (SD) postoperative stays: after lidocaine, 3.3 (0.9) days vs 3.4 (0.7) days, p = 0.90; or after saline, 4.7 (2.3) days vs 4.5 (5.1) days, p = 0.89. Lidocaine reduced the time to mobilisation by a mean (95% CI) of 4.6 (2.5-6.7) h, p = 0.001, from a mean (SD) of 22.0 (4.4) h after saline. Water was tolerated a mean (95% CI) of 3.9 (1.5-6.3) postoperative hours sooner after lidocaine, p = 0.002, than the mean (SD) of 13.6 (5.0) h after saline. Similarly, food was tolerated a mean (95% CI) of 5.4 (2.1-8.6) h sooner after lidocaine, p = 0.002, than the mean (SD) of 20.9 (7.5) h after saline. Lidocaine reduced pain at rest during the first 24 postoperative hours by a mean (95% CI) of 1.8 (0.7-2.9) mm.h À1 , p = 0.001 (Fig. 3) . The change in pain scores during movement in the first 24 postoperative hours was similar between the groups with a mean with saline, p = 0.14. There were no differences in other outcomes (Table 2) .
Plasma lidocaine was not detectable after saline. Lidocaine infusions resulted in mean (SD) plasma concentrations of 1.36 (0.48) lg.ml À1 in recovery (maximum 2.80 lg.ml À1 ) and 3.20 (0.95) lg.ml À1 at 24 h (maximum 4.96 lg.ml À1 ). Plasma lidocaine levels did not correlate with cumulative morphine consumption, r = 0.09, p = 0.6.
Discussion
Peri-operative infusions of lidocaine up to 24 postoperative hours reduced pain, morphine consumption and hospital stay following radical prostatectomy. Subcutaneous lidocaine can result in stable therapeutic plasma lidocaine concentrations [9, 10] . We modelled the subcutaneous lidocaine infusion regime on the doses described by studies of intravenous lidocaine [11, 12] . The lidocaine plasma levels that we measured were similar to those studies (2-5 mg.ml
À1
).
Postoperative intravenous lidocaine infusions can reduce pain and postoperative stay [13, 14] . The similarity of our results suggests that subcutaneous lidocaine may be equivalent to intravenous infusion, Figure 4 Cumulative postoperative morphine consumption after peri-operative infusions of lidocaine ( ) or saline ( ). Values are mean (SD). although this should be tested within a randomised controlled trial. We do not know what plasma lidocaine concentrations might result from continuation of the subcutaneous infusion beyond 24 h. We do not know whether our results are applicable to other scheduled (or emergency) major abdominal operations or to older, sicker or obese patients. We do not know how much the effects of peri-operative lidocaine were the result of pre-operative bolus, intraoperative intravenous infusion or postoperative subcutaneous infusion. We cannot extrapolate our lidocaine infusion results to different combinations of rate, duration or route. We cannot exclude important plasma lidocaine levels between the two sampling times. We did not measure concentrations of active but less potent lidocaine metabolites, including monoethyluglycinexylidide and glycinexylidide.
In summary, a combination of peri-operative intravenous and subcutaneous lidocaine, up to 24 hours after radical prostatectomy, reduced pain, morphine consumption and hospital stay compared with saline.
